Dear Shareholder

In these unprecedented times, I am writing to inform you of important changes to the arrangements for the Annual General Meeting (AGM) of AstraZeneca PLC (the Company). The AGM will take place at the scheduled time and date of 2.30pm BST on Wednesday 29 April 2020 but will now take place as a closed meeting. It will not be possible for shareholders to attend the meeting in person.

The Board of Directors of the Company (the Board) has been closely monitoring the evolving COVID-19 situation. The safety and security of our workforce and our shareholders is paramount and therefore, in compliance with the ‘Stay at Home Measures’ passed into law in England and Wales on 26 March 2020, we have taken the following decisions:

- We are required to hold an AGM and we will do so under the ‘essential work purposes’ exemption.
- The AGM will not take place at Leonardo Royal Hotel London Tower Bridge, but will instead take place behind closed doors at the Company’s corporate office at Academy House, 136 Hills Road, Cambridge, CB2 8PA. Only formal business will be conducted and there will be no speeches.
- We will arrange for a sufficient number of shareholders to attend to constitute the required quorum so that the AGM is validly held. These shareholders will be employees of the Company and will ensure appropriate social distancing and other measures.
- Other shareholders, corporate representatives and persons usually entitled to attend the AGM will not be permitted to attend the meeting in person on the grounds of public safety.
- Shareholders are strongly encouraged to appoint the Chairman of the AGM as their proxy. This means that the Chairman of the AGM will be able to vote on their behalf, and in accordance with their instructions, at the AGM. Any other proxy appointees will not be permitted to attend the meeting in person.
- The Company will publish the results of the AGM through a Regulatory Information Service and on the Company’s website at www.astrazeneca.com/agm in the usual fashion, as soon as practicable following the conclusion of the AGM.

Further details about these new arrangements for the AGM, including how to appoint the Chairman of the AGM as proxy, are included in the questions and answers at the end of this letter. As a Board, engagement with shareholders remains of the upmost importance to us and we hope that you appreciate why the exceptional nature of the current circumstances has led us to makes these changes.

As shareholders will not be able to pose questions to the Board directly at this year’s AGM, shareholders are invited to submit their questions using the postal or email addresses provided below. We will endeavour, where appropriate, to respond to these questions as soon as practicable after the AGM.
Further, we intend to organise an event for retail shareholders to attend and engage with Directors. Details about this event will be finalised and communicated to shareholders via the Company’s website once we have more clarity about timing, as it must be safe and permissible for such an event to take place.

The Company is also scheduled to publish its results for the first quarter of 2020 on 29 April 2020, which will provide an update on the Company’s performance for shareholders.

Finally, let me emphasise how much the Board values the support of shareholders. We send our very best wishes to you and your families, in these challenging times.

Leif Johansson
Chairman
17 April 2020
Questions and Answers

Can I attend the AGM?

Public gatherings of more than two people are not permitted under the compulsory ‘Stay at Home Measures’ passed into law in England and Wales on 26 March 2020, other than for limited exceptional purposes. Attendance by a shareholder at a company’s general meeting does not fall within those exceptions. Therefore, shareholders are not permitted to attend the AGM. Any shareholder or other person that arrives at the AGM venue will not be admitted to the building.

How can I vote on the resolutions at the AGM?

Although shareholders are not permitted to attend the AGM, all shareholders are strongly encouraged to vote on the AGM resolutions by appointing the Chairman of the AGM as their proxy. When a shareholder appoints the Chairman of the AGM as their proxy, the person who chairs the AGM will be able to vote on that shareholder’s behalf, casting those votes in accordance with the shareholder’s instructions.

Instructions as to how to appoint the Chairman of the AGM as proxy are included in the Notice of Annual General Meeting 2020 published in March 2020, available at www.astrazeneca.com/agm, and are also included on proxy cards or voting forms sent to shareholders. The deadlines for lodging proxy votes stated in the Notice of Annual General Meeting 2020 will not change, providing the AGM takes place at the scheduled time.

Holders of AstraZeneca American Depositary Receipts (ADRs), and holders of AstraZeneca ordinary shares that are listed in Stockholm should follow the specific instructions contained in the tailored shareholder communications that were sent to them in March 2020. The deadlines for lodging proxy votes stated in those additional communications will not change, providing the AGM takes place at the scheduled time.

Contact details for shareholders that require further assistance in appointing the Chairman of the AGM as their proxy are included at the end of this document.

Has the timing of the AGM changed?

Our current intention is that the AGM will commence at the scheduled time, being 14:30 BST on 29 April 2020. However, the AGM will no longer take place at Leonardo Royal Hotel London Tower Bridge and instead will take place behind closed doors at the Company’s corporate office at Academy House, 136 Hills Road, Cambridge, CB2 8PA.

How can I ask the Board a question?

Face-to-face engagement with shareholders is of utmost important to the Board. As we will not be able to answer shareholder questions at the AGM in the usual fashion, shareholders are invited to submit questions by email to AGM2020questions@astrazeneca.com or by post to AstraZeneca PLC – AGM Questions, Academy House, 136 Hills Road, Cambridge, CB2 8PA. We will endeavour to answer these questions as soon as practicable after the AGM.

We intend to organise an event for our retail shareholders to attend and engage with Directors. Details about this event will be finalised and communicated to shareholders via the Company’s website once we have more clarity about timing, as it must be safe and permissible for such an event to take place.

How will I know what the AGM voting outcomes are?

The Company will publish the results of the AGM through a Regulatory Information Service and on the Company’s website at www.astrazeneca.com/agm in the usual fashion, as soon as practicable following the conclusion of the AGM.
Shareholder Contact Information

Ordinary Share Registrar
Equiniti
Aspect House Spencer Road
Lancing West
Sussex
BN99 6DA
UK
Tel: (freephone in the UK) 0800 389 1580
Tel: (outside the UK) +44 (0)121 415 7033

Swedish Central Securities Depository
Euroclear Sweden AB
PO Box 191
SE-101 23 Stockholm
Sweden
Tel: +46 (0)8 402 9000

US Depositary
Deutsche Bank Trust Company Americas
c/o American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
USA
Tel: (toll free in the US) 888 697 8018
Tel: (outside the US) +1 718 921 8137